



## Clinical trial results:

**An open-label, multi-center, single-arm study to evaluate the efficacy of nilotinib in adult patients with metastatic or unresectable gastrointestinal stromal tumors in first line treatment**

### Summary

EudraCT number	2008-000358-11
Trial protocol	DE ES FI IT FR
Global end of trial date	18 December 2024

### Results information

Result version number	v1 (current)
This version publication date	01 January 2026
First version publication date	01 January 2026

### Trial information

#### Trial identification

Sponsor protocol code	CAMN107DDE06
-----------------------	--------------

#### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT00756509
WHO universal trial number (UTN)	-

Notes:

### Sponsors

Sponsor organisation name	Novartis Pharmaceuticals
Sponsor organisation address	CH-4002, Basel, Switzerland,
Public contact	Clinical Disclosure Office, Novartis Pharma AG, 41 613241111, novartis.email@novartis.com
Scientific contact	Clinical Disclosure Office, Novartis Pharmaceuticals, 41 613241111, novartis.email@novartis.com

Notes:

### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	18 December 2024
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	18 December 2024
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

The main objective of the trial was to evaluate the efficacy of Nilotinib in participants with unresectable or metastatic gastrointestinal stromal tumors. Efficacy was defined as the proportion of patients showing stable disease (SD), partial response (PR) or complete response (CR) during the first 6 months, core phase, according to RECIST criteria.

Due to EudraCT system limitations, which EMA is aware of, data using 9999 as data points in this record are not an accurate representation of the clinical trial results. Please use <https://www.novctrd.com/CtrdWeb/home.nov> for complete trial results.

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and the International Conference on Harmonization (ICH) Good Clinical Practice (GCP) guidelines. All the local regulatory requirements pertinent to safety of trial subjects were also followed during the conduct of the trial.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	26 August 2008
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Finland: 5
Country: Number of subjects enrolled	France: 2
Country: Number of subjects enrolled	Germany: 15
Country: Number of subjects enrolled	Italy: 9
Country: Number of subjects enrolled	Spain: 10
Worldwide total number of subjects	41
EEA total number of subjects	41

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0

Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	28
From 65 to 84 years	13
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

Study consists of participants with unresectable or metastatic gastrointestinal stromal tumors (GIST) showing progression of disease from 5 countries: Germany, Spain, Finland, France, Italy

### Pre-assignment

Screening details:

All enrolled participants received 400 mg bid dose of nilotinib.

### Period 1

Period 1 title	Core Phase
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

### Arms

Arm title	Nilotinib
-----------	-----------

Arm description:

Participants who received 400 mg bid of nilotinib

Arm type	Experimental
Investigational medicinal product name	Nilotinib
Investigational medicinal product code	AMN107
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

400 mg bid of nilotinib

Number of subjects in period 1	Nilotinib
Started	41
Completed	31
Not completed	10
Disease progression	6
Adverse event, non-fatal	2
Lack of efficacy	2

### Period 2

Period 2 title	Follow-Up Phase
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Not blinded

## Arms

Arm title	Nilotinib
-----------	-----------

Arm description:

Participants who received 400 mg bid of nilotinib

Arm type	Experimental
Investigational medicinal product name	Nilotinib
Investigational medicinal product code	AMN107
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

400 mg bid of nilotinib

Number of subjects in period 2	Nilotinib
Started	31
Completed	7
Not completed	24
Consent withdrawn by subject	1
Disease progression	9
Missing values	2
Adverse event, non-fatal	7
Administrative problems	3
Lost to follow-up	1
Subject's condition no longer requires study drug	1

## Baseline characteristics

### Reporting groups

Reporting group title	Nilotinib
-----------------------	-----------

Reporting group description:

Participants who received 400 mg bid of nilotinib

Reporting group values	Nilotinib	Total	
Number of subjects	41	41	
Age categorical			
Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	28	28	
From 65-84 years	13	13	
85 years and over	0	0	
Age Continuous			
Units: Years			
arithmetic mean	58		
standard deviation	± 10.4	-	
Sex: Female, Male			
Units: Participants			
Female	19	19	
Male	22	22	
Race/Ethnicity, Customized			
Units: Subjects			
Caucasian	40	40	
Black	1	1	

## End points

### End points reporting groups

Reporting group title	Nilotinib
Reporting group description:	
Participants who received 400 mg bid of nilotinib	
Reporting group title	Nilotinib
Reporting group description:	
Participants who received 400 mg bid of nilotinib	

### Primary: Proportion of participants with Best Overall Response at month 6 (core phase) determined according to the RECIST v1.0.

End point title	Proportion of participants with Best Overall Response at month 6 (core phase) determined according to the RECIST v1.0. <sup>[1]</sup>
End point description:	
The primary efficacy measure is the proportion of patients reaching Complete Response (CR), Partial Response (PR), or Stable Disease (SD) by Month 6, as per RECIST v1.0. Definitions are as follows: CR requires at least two CRs at least four weeks apart before any progression; PR requires two or more PRs at least four weeks apart, without qualifying for CR; SD is at least one SD more than six weeks after treatment start, not qualifying for CR or PR. Progressive Disease (PD) is defined as progression or cancer-related death within 12 weeks of starting treatment, not qualifying for CR, PR, or SD. UNK refers to cases not meeting these criteria, such as absence of confirmed CR/PR, no SD after six weeks, or early progression. The percentage of patients with CR, PR, or SD will be presented with a one-sided exact 90% (or 80% two-sided) confidence interval for the ITT_F group.	
End point type	Primary
End point timeframe:	
from baseline to month 6, core phase	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analysis was planned for this primary outcome

End point values	Nilotinib			
Subject group type	Reporting group			
Number of subjects analysed	41			
Units: Participants				
Complete Response (CR)	0			
Partial Response (PR)	14			
Stable Disease (SD)	21			
Progressive Disease (PD)	6			
Unknown (UNK)	0			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Proportion of participants with Objective Response Rate (ORR) at month 6 (core phase) observed according to RECIST

End point title	Proportion of participants with Objective Response Rate (ORR)
-----------------	---

End point description:

Objective Response Rate (ORR) is defined as the proportion of patients in whom a complete (CR) or partial (PR) response was observed according to RECIST at month 6.

End point type	Secondary
----------------	-----------

End point timeframe:

from baseline to month 6, core phase

End point values	Nilotinib			
Subject group type	Reporting group			
Number of subjects analysed	41			
Units: Percentage of responder				
number (confidence interval 80%)	34.1 (24.2 to 45.3)			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Progression-free survival (PFS) for complete study (core and follow-up phases)

End point title	Progression-free survival (PFS) for complete study (core and follow-up phases)
-----------------	--

End point description:

Progression-free survival (PFS) is defined as the time from first study drug administration to objective tumor progression or death from any cause. If a patient has not had an event, PFS is censored at the date of last adequate tumor assessment. PFS will be explored graphically by presenting the Kaplan-Meier curve.

End point type	Secondary
----------------	-----------

End point timeframe:

from date of first response (CR or PR) until progression or death, up to data cut off (up to approximately 16 years)

End point values	Nilotinib			
Subject group type	Reporting group			
Number of subjects analysed	31			
Units: Days				
median (confidence interval 95%)	2833 (791 to 9999)			

### Statistical analyses



No statistical analyses for this end point

---

**Secondary: Proportion of participants with treatment-emergent adverse events during the entire study (core and follow-up phases)**

---

End point title	Proportion of participants with treatment-emergent adverse events during the entire study (core and follow-up phases)
-----------------	---

End point description:

This measure summarizes the proportion of participants who experienced at least one treatment-emergent adverse event (TEAE) during the entire study period, including both core and follow-up phases. A TEAE was defined as an adverse event that began or worsened after the first dose of study treatment.

End point type	Secondary
----------------	-----------

End point timeframe:

from the first dose through the end of the study (core and follow-up phases): including all visits up to the follow-up database lock (approximately 16 years)

---

End point values	Nilotinib			
Subject group type	Reporting group			
Number of subjects analysed	41			
Units: Participants				
All AEs	39			

---

**Statistical analyses**

---

No statistical analyses for this end point

---

**Secondary: Duration of response (CR or PR) for complete study (core and follow-up phases)**

---

End point title	Duration of response (CR or PR) for complete study (core and follow-up phases)
-----------------	--

End point description:

Duration of response is defined as the time from onset of response (CR/PR) to objective tumor progression or death from any cause. Patients not experiencing progression or death will be censored with the date of their last adequate tumor assessment.

End point type	Secondary
----------------	-----------

End point timeframe:

from date of first response (CR or PR) until progression or death, up to data cut off (up to approximately 16 years)

---

End point values	Nilotinib			
Subject group type	Reporting group			
Number of subjects analysed	21			
Units: Days				
median (confidence interval 95%)	2722 (588 to 9999)			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Time to Response (TTR) at Month 6 (core phase)

End point title	Time to Response (TTR) at Month 6 (core phase)
-----------------	--

End point description:

Time to response is defined as the time from start of treatment to the first objective tumor response (PR or CR) observed. Patients who did not achieve a confirmed PR or CR will be censored at last adequate tumor assessment date when they did not progress (including deaths not due to underlying disease).

End point type	Secondary
----------------	-----------

End point timeframe:

from baseline to month 6, core phase

End point values	Nilotinib			
Subject group type	Reporting group			
Number of subjects analysed	41			
Units: Days				
median (confidence interval 95%)	62 (57 to 999)			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Overall Survival for complete study (core and follow-up phases)

End point title	Overall Survival for complete study (core and follow-up phases)
-----------------	---

End point description:

Overall Survival (OS) is defined as the time from first study drug administration to death from any cause. Participants alive at their last known follow-up were censored. No deaths occurred during the study.

End point type	Secondary
----------------	-----------

End point timeframe:

from date of first response (CR or PR) until progression or death, up to data cut off (up to approximately 16 years)

<b>End point values</b>	Nilotinib			
Subject group type	Reporting group			
Number of subjects analysed	0 <sup>[2]</sup>			
Units: Participants				

Notes:

[2] - No deaths occurred, so no participants were included in the survival analysis.

## Statistical analyses

---

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Adverse events were collected from first dose through the end of the study (core and follow-up phases), including all visits up to the follow-up database lock (approximately 16 years).

Adverse event reporting additional description:

Any signs or symptoms were collected from first dose through the end of the study (core and follow-up phases), including all visits up to the follow-up database lock (approximately 16 years).

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	27.1
--------------------	------

### Reporting groups

Reporting group title	Total Follow up
-----------------------	-----------------

Reporting group description:

Total Follow up Phase

Reporting group title	Total Core
-----------------------	------------

Reporting group description:

Total Core Phase

Serious adverse events	Total Follow up	Total Core	
Total subjects affected by serious adverse events			
subjects affected / exposed	14 / 31 (45.16%)	10 / 41 (24.39%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
TUMOUR RUPTURE			
subjects affected / exposed	0 / 31 (0.00%)	1 / 41 (2.44%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
KERATOACANTHOMA			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
PLASMA CELL MYELOMA			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Vascular disorders			
ARTERIAL THROMBOSIS			
subjects affected / exposed	0 / 31 (0.00%)	1 / 41 (2.44%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
CIRCULATORY COLLAPSE			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
PERIPHERAL ARTERIAL OCCLUSIVE DISEASE			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences causally related to treatment / all	1 / 10	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
PYREXIA			
subjects affected / exposed	2 / 31 (6.45%)	2 / 41 (4.88%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
CHEST PAIN			
subjects affected / exposed	0 / 31 (0.00%)	1 / 41 (2.44%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
VASCULAR STENT STENOSIS			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
HYPERPLASIA			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
GENERAL PHYSICAL HEALTH DETERIORATION			

subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immune system disorders			
MULTIPLE SCLEROSIS RELAPSE			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
PULMONARY HYPERTENSION			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
PLEURAL EFFUSION			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychiatric disorders			
DEPRESSION			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Investigations			
HAEMOGLOBIN DECREASED			
subjects affected / exposed	0 / 31 (0.00%)	1 / 41 (2.44%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
ARTERIAL RESTENOSIS			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
MYOCARDIAL INFARCTION			

subjects affected / exposed	1 / 31 (3.23%)	1 / 41 (2.44%)	
occurrences causally related to treatment / all	1 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
CARDIAC FAILURE			
subjects affected / exposed	2 / 31 (6.45%)	0 / 41 (0.00%)	
occurrences causally related to treatment / all	2 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
CARDIAC FAILURE CHRONIC			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
CARDIAC FAILURE CONGESTIVE			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
CARDIO-RESPIRATORY ARREST			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
PERICARDIAL EFFUSION			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
SUPRAVENTRICULAR TACHYCARDIA			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
CORONARY ARTERY DISEASE			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
NEURITIS			

subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
HEADACHE			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
CAROTID ARTERY STENOSIS			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ear and labyrinth disorders			
VESTIBULAR DISORDER			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
VERTIGO			
subjects affected / exposed	2 / 31 (6.45%)	0 / 41 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye disorders			
GLAUCOMA			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
OCULAR HYPERTENSION			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
DIARRHOEA			
subjects affected / exposed	0 / 31 (0.00%)	1 / 41 (2.44%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	



ABDOMINAL PAIN			
subjects affected / exposed	2 / 31 (6.45%)	2 / 41 (4.88%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
SUBILEUS			
subjects affected / exposed	0 / 31 (0.00%)	1 / 41 (2.44%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
CHOLELITHIASIS			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
ACUTE KIDNEY INJURY			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endocrine disorders			
TOXIC NODULAR GOITRE			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
SEPSIS			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
INFECTION			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
STREPTOCOCCAL SEPSIS			

subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
HYPERCALCAEMIA			
subjects affected / exposed	0 / 31 (0.00%)	1 / 41 (2.44%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 2 %

Non-serious adverse events	Total Follow up	Total Core	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	28 / 31 (90.32%)	39 / 41 (95.12%)	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
SKIN PAPILLOMA			
subjects affected / exposed	2 / 31 (6.45%)	1 / 41 (2.44%)	
occurrences (all)	2	1	
SPINAL HAEMANGIOMA			
subjects affected / exposed	0 / 31 (0.00%)	1 / 41 (2.44%)	
occurrences (all)	0	1	
BASAL CELL CARCINOMA			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences (all)	1	0	
HAEMANGIOMA OF BONE			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences (all)	1	0	
PAPILLOMA			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences (all)	1	0	
Vascular disorders			
ARTERIOSCLEROSIS			
subjects affected / exposed	2 / 31 (6.45%)	1 / 41 (2.44%)	
occurrences (all)	2	1	
HOT FLUSH			

subjects affected / exposed	1 / 31 (3.23%)	2 / 41 (4.88%)	
occurrences (all)	1	2	
HYPERTENSION			
subjects affected / exposed	2 / 31 (6.45%)	1 / 41 (2.44%)	
occurrences (all)	2	1	
PERIPHERAL COLDNESS			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences (all)	1	0	
PERIPHERAL ARTERIAL OCCLUSIVE DISEASE			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences (all)	3	0	
INTERMITTENT CLAUDICATION			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences (all)	2	0	
HYPERTENSIVE CRISIS			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences (all)	1	0	
AORTIC ANEURYSM			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences (all)	1	0	
VENOUS THROMBOSIS			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences (all)	1	0	
ANEURYSM			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences (all)	1	0	
Surgical and medical procedures			
VITRECTOMY			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences (all)	1	0	
GASTROOESOPHAGEAL REFLUX PROPHYLAXIS			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences (all)	1	0	
ASTRINGENT THERAPY			

subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences (all)	1	0	
General disorders and administration site conditions			
PYREXIA			
subjects affected / exposed	3 / 31 (9.68%)	2 / 41 (4.88%)	
occurrences (all)	10	4	
ASTHENIA			
subjects affected / exposed	2 / 31 (6.45%)	11 / 41 (26.83%)	
occurrences (all)	3	11	
CHEST DISCOMFORT			
subjects affected / exposed	0 / 31 (0.00%)	1 / 41 (2.44%)	
occurrences (all)	0	1	
CHEST PAIN			
subjects affected / exposed	0 / 31 (0.00%)	1 / 41 (2.44%)	
occurrences (all)	0	2	
FACE OEDEMA			
subjects affected / exposed	0 / 31 (0.00%)	1 / 41 (2.44%)	
occurrences (all)	0	1	
FATIGUE			
subjects affected / exposed	5 / 31 (16.13%)	10 / 41 (24.39%)	
occurrences (all)	9	12	
FEELING COLD			
subjects affected / exposed	1 / 31 (3.23%)	2 / 41 (4.88%)	
occurrences (all)	2	2	
LOCAL SWELLING			
subjects affected / exposed	0 / 31 (0.00%)	1 / 41 (2.44%)	
occurrences (all)	0	1	
MUCOSAL INFLAMMATION			
subjects affected / exposed	1 / 31 (3.23%)	1 / 41 (2.44%)	
occurrences (all)	1	1	
OEDEMA			
subjects affected / exposed	1 / 31 (3.23%)	1 / 41 (2.44%)	
occurrences (all)	1	1	
OEDEMA PERIPHERAL			

subjects affected / exposed	7 / 31 (22.58%)	8 / 41 (19.51%)	
occurrences (all)	17	10	
THIRST			
subjects affected / exposed	0 / 31 (0.00%)	1 / 41 (2.44%)	
occurrences (all)	0	1	
INFLAMMATION			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences (all)	1	0	
INFUSION SITE EXTRAVASATION			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences (all)	1	0	
MALAISE			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences (all)	1	0	
PSEUDOCYST			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences (all)	1	0	
Immune system disorders			
MULTIPLE SCLEROSIS RELAPSE			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences (all)	2	0	
MULTIPLE SCLEROSIS			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences (all)	1	0	
Reproductive system and breast disorders			
ERECTILE DYSFUNCTION			
subjects affected / exposed	1 / 31 (3.23%)	2 / 41 (4.88%)	
occurrences (all)	1	2	
NIPPLE OEDEMA			
subjects affected / exposed	0 / 31 (0.00%)	1 / 41 (2.44%)	
occurrences (all)	0	1	
NIPPLE PAIN			
subjects affected / exposed	0 / 31 (0.00%)	1 / 41 (2.44%)	
occurrences (all)	0	1	
PELVIC PAIN			

subjects affected / exposed	0 / 31 (0.00%)	1 / 41 (2.44%)	
occurrences (all)	0	1	
TESTIS DISCOMFORT			
subjects affected / exposed	0 / 31 (0.00%)	1 / 41 (2.44%)	
occurrences (all)	0	1	
Respiratory, thoracic and mediastinal disorders			
DYSпноEA			
subjects affected / exposed	1 / 31 (3.23%)	2 / 41 (4.88%)	
occurrences (all)	3	2	
COUGH			
subjects affected / exposed	3 / 31 (9.68%)	2 / 41 (4.88%)	
occurrences (all)	4	2	
DYSPHONIA			
subjects affected / exposed	1 / 31 (3.23%)	1 / 41 (2.44%)	
occurrences (all)	1	3	
PLEURAL EFFUSION			
subjects affected / exposed	3 / 31 (9.68%)	1 / 41 (2.44%)	
occurrences (all)	3	1	
THROAT IRRITATION			
subjects affected / exposed	1 / 31 (3.23%)	1 / 41 (2.44%)	
occurrences (all)	1	2	
SLEEP APNOEA SYNDROME			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences (all)	1	0	
PLEURITIC PAIN			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences (all)	1	0	
HIATUS HERNIA			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences (all)	1	0	
EMPHYSEMA			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences (all)	1	0	
CATARRH			

subjects affected / exposed occurrences (all)	1 / 31 (3.23%) 1	0 / 41 (0.00%) 0	
Psychiatric disorders			
ANXIETY			
subjects affected / exposed	1 / 31 (3.23%)	2 / 41 (4.88%)	
occurrences (all)	1	2	
ILLUSION			
subjects affected / exposed	0 / 31 (0.00%)	1 / 41 (2.44%)	
occurrences (all)	0	1	
NERVOUSNESS			
subjects affected / exposed	0 / 31 (0.00%)	1 / 41 (2.44%)	
occurrences (all)	0	1	
RESTLESSNESS			
subjects affected / exposed	1 / 31 (3.23%)	1 / 41 (2.44%)	
occurrences (all)	1	1	
SLEEP DISORDER			
subjects affected / exposed	1 / 31 (3.23%)	1 / 41 (2.44%)	
occurrences (all)	1	1	
INSOMNIA			
subjects affected / exposed	0 / 31 (0.00%)	1 / 41 (2.44%)	
occurrences (all)	0	1	
ANXIETY DISORDER			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences (all)	1	0	
PANIC ATTACK			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences (all)	1	0	
MOOD SWINGS			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences (all)	1	0	
CONFUSIONAL STATE			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences (all)	1	0	
Investigations			
ALANINE AMINOTRANSFERASE INCREASED			

subjects affected / exposed	3 / 31 (9.68%)	2 / 41 (4.88%)
occurrences (all)	4	3
BLOOD AMYLASE INCREASED		
subjects affected / exposed	0 / 31 (0.00%)	1 / 41 (2.44%)
occurrences (all)	0	1
BLOOD CREATININE INCREASED		
subjects affected / exposed	1 / 31 (3.23%)	1 / 41 (2.44%)
occurrences (all)	1	1
BLOOD GLUCOSE INCREASED		
subjects affected / exposed	1 / 31 (3.23%)	1 / 41 (2.44%)
occurrences (all)	1	1
GAMMA-GLUTAMYLTRANSFERASE INCREASED		
subjects affected / exposed	1 / 31 (3.23%)	2 / 41 (4.88%)
occurrences (all)	1	2
LIPASE INCREASED		
subjects affected / exposed	3 / 31 (9.68%)	1 / 41 (2.44%)
occurrences (all)	5	1
TRANSAMINASES INCREASED		
subjects affected / exposed	2 / 31 (6.45%)	5 / 41 (12.20%)
occurrences (all)	2	6
BLOOD BILIRUBIN INCREASED		
subjects affected / exposed	2 / 31 (6.45%)	1 / 41 (2.44%)
occurrences (all)	4	1
CARDIAC MURMUR		
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)
occurrences (all)	1	0
C-REACTIVE PROTEIN INCREASED		
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)
occurrences (all)	1	0
ASPARTATE AMINOTRANSFERASE INCREASED		
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)
occurrences (all)	1	0
AMYLASE INCREASED		



subjects affected / exposed	3 / 31 (9.68%)	0 / 41 (0.00%)	
occurrences (all)	3	0	
COLONOSCOPY			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences (all)	1	0	
ELECTROCARDIOGRAM QT PROLONGED			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences (all)	1	0	
INTRAOCULAR PRESSURE INCREASED			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences (all)	1	0	
Injury, poisoning and procedural complications			
ARTHROPOD BITE			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences (all)	1	0	
CONTUSION			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences (all)	1	0	
FRACTURE			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences (all)	1	0	
JOINT DISLOCATION			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences (all)	1	0	
WOUND			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences (all)	1	0	
THORACIC VERTEBRAL FRACTURE			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences (all)	1	0	
SPLINTER			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences (all)	1	0	
SKIN ABRASION			

subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences (all)	1	0	
RIB FRACTURE			
subjects affected / exposed	2 / 31 (6.45%)	0 / 41 (0.00%)	
occurrences (all)	3	0	
Cardiac disorders			
PALPITATIONS			
subjects affected / exposed	1 / 31 (3.23%)	2 / 41 (4.88%)	
occurrences (all)	1	2	
ANGINA PECTORIS			
subjects affected / exposed	2 / 31 (6.45%)	0 / 41 (0.00%)	
occurrences (all)	2	0	
CARDIAC FAILURE CONGESTIVE			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences (all)	1	0	
CORONARY ARTERY DISEASE			
subjects affected / exposed	2 / 31 (6.45%)	0 / 41 (0.00%)	
occurrences (all)	2	0	
MITRAL VALVE INCOMPETENCE			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences (all)	1	0	
PERICARDIAL EFFUSION			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences (all)	1	0	
Nervous system disorders			
DIZZINESS			
subjects affected / exposed	3 / 31 (9.68%)	2 / 41 (4.88%)	
occurrences (all)	3	2	
DYSGEUSIA			
subjects affected / exposed	2 / 31 (6.45%)	4 / 41 (9.76%)	
occurrences (all)	2	4	
HEADACHE			
subjects affected / exposed	5 / 31 (16.13%)	11 / 41 (26.83%)	
occurrences (all)	7	11	
MEMORY IMPAIRMENT			

subjects affected / exposed	0 / 31 (0.00%)	1 / 41 (2.44%)
occurrences (all)	0	1
PARAESTHESIA		
subjects affected / exposed	5 / 31 (16.13%)	1 / 41 (2.44%)
occurrences (all)	7	1
PERIPHERAL SENSORY NEUROPATHY		
subjects affected / exposed	2 / 31 (6.45%)	2 / 41 (4.88%)
occurrences (all)	4	2
CAROTID ARTERY STENOSIS		
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)
occurrences (all)	1	0
CEREBROVASCULAR DISORDER		
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)
occurrences (all)	1	0
DECREASED VIBRATORY SENSE		
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)
occurrences (all)	1	0
DISTURBANCE IN ATTENTION		
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)
occurrences (all)	1	0
HYPOAESTHESIA		
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)
occurrences (all)	1	0
NYSTAGMUS		
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)
occurrences (all)	1	0
PARESIS		
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)
occurrences (all)	1	0
PARTIAL SEIZURES		
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)
occurrences (all)	1	0
POLYNEUROPATHY		
subjects affected / exposed	2 / 31 (6.45%)	0 / 41 (0.00%)
occurrences (all)	2	0
VASCULAR DEMENTIA		

subjects affected / exposed occurrences (all)	1 / 31 (3.23%) 1	0 / 41 (0.00%) 0	
Blood and lymphatic system disorders			
ANAEMIA			
subjects affected / exposed	4 / 31 (12.90%)	2 / 41 (4.88%)	
occurrences (all)	4	2	
NEUTROPENIA			
subjects affected / exposed	0 / 31 (0.00%)	1 / 41 (2.44%)	
occurrences (all)	0	1	
AGRANULOCYTOSIS			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences (all)	1	0	
SPLENIC INFARCTION			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences (all)	1	0	
Ear and labyrinth disorders			
HYPOACUSIS			
subjects affected / exposed	1 / 31 (3.23%)	1 / 41 (2.44%)	
occurrences (all)	1	1	
EAR SWELLING			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences (all)	1	0	
EXTERNAL EAR INFLAMMATION			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences (all)	1	0	
TINNITUS			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences (all)	1	0	
VERTIGO			
subjects affected / exposed	5 / 31 (16.13%)	0 / 41 (0.00%)	
occurrences (all)	7	0	
Eye disorders			
OCULAR HYPERAEMIA			
subjects affected / exposed	0 / 31 (0.00%)	1 / 41 (2.44%)	
occurrences (all)	0	1	
ABNORMAL SENSATION IN EYE			

subjects affected / exposed	0 / 31 (0.00%)	1 / 41 (2.44%)	
occurrences (all)	0	1	
DRY EYE			
subjects affected / exposed	1 / 31 (3.23%)	1 / 41 (2.44%)	
occurrences (all)	3	2	
EYELID PAIN			
subjects affected / exposed	1 / 31 (3.23%)	1 / 41 (2.44%)	
occurrences (all)	1	1	
CONJUNCTIVAL HAEMORRHAGE			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences (all)	1	0	
EYE PAIN			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences (all)	1	0	
GLAUCOMA			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences (all)	1	0	
OCULAR HYPERTENSION			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences (all)	1	0	
PERIORBITAL OEDEMA			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences (all)	1	0	
Gastrointestinal disorders			
ABDOMINAL PAIN			
subjects affected / exposed	8 / 31 (25.81%)	11 / 41 (26.83%)	
occurrences (all)	11	15	
ABDOMINAL PAIN LOWER			
subjects affected / exposed	1 / 31 (3.23%)	1 / 41 (2.44%)	
occurrences (all)	1	1	
ABDOMINAL PAIN UPPER			
subjects affected / exposed	0 / 31 (0.00%)	4 / 41 (9.76%)	
occurrences (all)	0	4	
CONSTIPATION			
subjects affected / exposed	9 / 31 (29.03%)	7 / 41 (17.07%)	
occurrences (all)	13	8	

GASTRITIS EROSIVE			
subjects affected / exposed	0 / 31 (0.00%)	1 / 41 (2.44%)	
occurrences (all)	0	1	
DYSPEPSIA			
subjects affected / exposed	2 / 31 (6.45%)	1 / 41 (2.44%)	
occurrences (all)	3	1	
DYSPHAGIA			
subjects affected / exposed	0 / 31 (0.00%)	1 / 41 (2.44%)	
occurrences (all)	0	1	
FLATULENCE			
subjects affected / exposed	2 / 31 (6.45%)	4 / 41 (9.76%)	
occurrences (all)	2	5	
GASTRIC POLYPS			
subjects affected / exposed	1 / 31 (3.23%)	1 / 41 (2.44%)	
occurrences (all)	1	1	
DIARRHOEA			
subjects affected / exposed	3 / 31 (9.68%)	8 / 41 (19.51%)	
occurrences (all)	9	11	
GASTROOESOPHAGEAL REFLUX DISEASE			
subjects affected / exposed	1 / 31 (3.23%)	2 / 41 (4.88%)	
occurrences (all)	1	2	
HIATUS HERNIA			
subjects affected / exposed	1 / 31 (3.23%)	1 / 41 (2.44%)	
occurrences (all)	1	1	
NAUSEA			
subjects affected / exposed	5 / 31 (16.13%)	8 / 41 (19.51%)	
occurrences (all)	8	8	
TOOTHACHE			
subjects affected / exposed	2 / 31 (6.45%)	1 / 41 (2.44%)	
occurrences (all)	2	1	
VOMITING			
subjects affected / exposed	4 / 31 (12.90%)	4 / 41 (9.76%)	
occurrences (all)	11	4	
HAEMORRHOIDS			

subjects affected / exposed	1 / 31 (3.23%)	1 / 41 (2.44%)	
occurrences (all)	1	1	
GASTRITIS HAEMORRHAGIC			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences (all)	1	0	
DRY MOUTH			
subjects affected / exposed	3 / 31 (9.68%)	0 / 41 (0.00%)	
occurrences (all)	4	0	
DIVERTICULUM INTESTINAL			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences (all)	1	0	
ASCITES			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences (all)	1	0	
AEROPHAGIA			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences (all)	1	0	
ABDOMINAL DISCOMFORT			
subjects affected / exposed	2 / 31 (6.45%)	0 / 41 (0.00%)	
occurrences (all)	7	0	
GINGIVAL RECESSION			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences (all)	1	0	
HAEMATOCHEZIA			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences (all)	1	0	
LIP ULCERATION			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences (all)	1	0	
REFLUX GASTRITIS			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences (all)	1	0	
EPIGASTRIC DISCOMFORT			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences (all)	1	0	
Hepatobiliary disorders			

HEPATOTOXICITY			
subjects affected / exposed	1 / 31 (3.23%)	3 / 41 (7.32%)	
occurrences (all)	1	3	
HYPERBILIRUBINAEMIA			
subjects affected / exposed	4 / 31 (12.90%)	6 / 41 (14.63%)	
occurrences (all)	4	7	
HYPERTRANSAMINASAEMIA			
subjects affected / exposed	0 / 31 (0.00%)	1 / 41 (2.44%)	
occurrences (all)	0	1	
HEPATITIS TOXIC			
subjects affected / exposed	0 / 31 (0.00%)	1 / 41 (2.44%)	
occurrences (all)	0	1	
CHOLELITHIASIS			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences (all)	1	0	
HEPATIC PAIN			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences (all)	1	0	
Skin and subcutaneous tissue disorders			
ALOPECIA			
subjects affected / exposed	9 / 31 (29.03%)	8 / 41 (19.51%)	
occurrences (all)	9	8	
DRY SKIN			
subjects affected / exposed	8 / 31 (25.81%)	8 / 41 (19.51%)	
occurrences (all)	11	11	
ECZEMA			
subjects affected / exposed	1 / 31 (3.23%)	3 / 41 (7.32%)	
occurrences (all)	1	4	
ERYTHEMA			
subjects affected / exposed	1 / 31 (3.23%)	1 / 41 (2.44%)	
occurrences (all)	1	1	
HYPERHIDROSIS			
subjects affected / exposed	1 / 31 (3.23%)	2 / 41 (4.88%)	
occurrences (all)	1	2	
NIGHT SWEATS			



subjects affected / exposed	1 / 31 (3.23%)	1 / 41 (2.44%)
occurrences (all)	3	1
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME		
subjects affected / exposed	2 / 31 (6.45%)	2 / 41 (4.88%)
occurrences (all)	2	2
PETECHIAE		
subjects affected / exposed	1 / 31 (3.23%)	1 / 41 (2.44%)
occurrences (all)	1	1
PHOTOSENSITIVITY REACTION		
subjects affected / exposed	2 / 31 (6.45%)	1 / 41 (2.44%)
occurrences (all)	2	1
PILOERECTION		
subjects affected / exposed	0 / 31 (0.00%)	1 / 41 (2.44%)
occurrences (all)	0	1
PRURITUS		
subjects affected / exposed	5 / 31 (16.13%)	11 / 41 (26.83%)
occurrences (all)	7	12
RASH		
subjects affected / exposed	6 / 31 (19.35%)	10 / 41 (24.39%)
occurrences (all)	7	14
XANTHELASMA		
subjects affected / exposed	1 / 31 (3.23%)	1 / 41 (2.44%)
occurrences (all)	1	1
ONYCHOCLASIS		
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)
occurrences (all)	1	0
NAIL DISORDER		
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)
occurrences (all)	1	0
HAIR COLOUR CHANGES		
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)
occurrences (all)	1	0
EYELID INFECTION		
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)
occurrences (all)	1	0

STASIS DERMATITIS			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences (all)	1	0	
SCAR PAIN			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences (all)	2	0	
Renal and urinary disorders			
HAEMATURIA			
subjects affected / exposed	0 / 31 (0.00%)	2 / 41 (4.88%)	
occurrences (all)	0	2	
NOCTURIA			
subjects affected / exposed	2 / 31 (6.45%)	1 / 41 (2.44%)	
occurrences (all)	3	1	
POLLAKIURIA			
subjects affected / exposed	1 / 31 (3.23%)	2 / 41 (4.88%)	
occurrences (all)	1	2	
RENAL FAILURE			
subjects affected / exposed	2 / 31 (6.45%)	1 / 41 (2.44%)	
occurrences (all)	2	1	
CALCULUS URINARY			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences (all)	1	0	
BLADDER DISCOMFORT			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences (all)	1	0	
CHRONIC KIDNEY DISEASE			
subjects affected / exposed	2 / 31 (6.45%)	0 / 41 (0.00%)	
occurrences (all)	2	0	
URINARY RETENTION			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences (all)	1	0	
DYSURIA			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences (all)	1	0	
Endocrine disorders			

GOITRE			
subjects affected / exposed	1 / 31 (3.23%)	1 / 41 (2.44%)	
occurrences (all)	1	1	
HYPERTHYROIDISM			
subjects affected / exposed	2 / 31 (6.45%)	0 / 41 (0.00%)	
occurrences (all)	2	0	
Musculoskeletal and connective tissue disorders			
FLANK PAIN			
subjects affected / exposed	0 / 31 (0.00%)	1 / 41 (2.44%)	
occurrences (all)	0	1	
ARTHRALGIA			
subjects affected / exposed	4 / 31 (12.90%)	8 / 41 (19.51%)	
occurrences (all)	5	8	
BACK PAIN			
subjects affected / exposed	5 / 31 (16.13%)	5 / 41 (12.20%)	
occurrences (all)	7	5	
BONE PAIN			
subjects affected / exposed	0 / 31 (0.00%)	1 / 41 (2.44%)	
occurrences (all)	0	1	
GROIN PAIN			
subjects affected / exposed	1 / 31 (3.23%)	1 / 41 (2.44%)	
occurrences (all)	1	1	
MUSCLE SPASMS			
subjects affected / exposed	5 / 31 (16.13%)	5 / 41 (12.20%)	
occurrences (all)	5	6	
MUSCLE TIGHTNESS			
subjects affected / exposed	0 / 31 (0.00%)	1 / 41 (2.44%)	
occurrences (all)	0	1	
MUSCULOSKELETAL PAIN			
subjects affected / exposed	1 / 31 (3.23%)	1 / 41 (2.44%)	
occurrences (all)	1	1	
MYALGIA			
subjects affected / exposed	3 / 31 (9.68%)	2 / 41 (4.88%)	
occurrences (all)	3	2	
NECK PAIN			

subjects affected / exposed	1 / 31 (3.23%)	1 / 41 (2.44%)	
occurrences (all)	1	1	
PAIN IN EXTREMITY			
subjects affected / exposed	4 / 31 (12.90%)	5 / 41 (12.20%)	
occurrences (all)	8	5	
JOINT SWELLING			
subjects affected / exposed	0 / 31 (0.00%)	1 / 41 (2.44%)	
occurrences (all)	0	1	
INTERVERTEBRAL DISC PROTRUSION			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences (all)	2	0	
MUSCULAR WEAKNESS			
subjects affected / exposed	2 / 31 (6.45%)	0 / 41 (0.00%)	
occurrences (all)	2	0	
OSTEOCHONDROSIS			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences (all)	1	0	
OSTEOARTHRITIS			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences (all)	2	0	
MUSCULOSKELETAL CHEST PAIN			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences (all)	1	0	
OSTEOLYSIS			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences (all)	1	0	
Infections and infestations			
CYSTITIS			
subjects affected / exposed	0 / 31 (0.00%)	1 / 41 (2.44%)	
occurrences (all)	0	1	
EAR INFECTION			
subjects affected / exposed	0 / 31 (0.00%)	1 / 41 (2.44%)	
occurrences (all)	0	1	
FEBRILE INFECTION			

subjects affected / exposed	0 / 31 (0.00%)	1 / 41 (2.44%)
occurrences (all)	0	1
GASTROENTERITIS		
subjects affected / exposed	1 / 31 (3.23%)	1 / 41 (2.44%)
occurrences (all)	1	1
HERPES ZOSTER		
subjects affected / exposed	1 / 31 (3.23%)	1 / 41 (2.44%)
occurrences (all)	1	1
NASOPHARYNGITIS		
subjects affected / exposed	6 / 31 (19.35%)	8 / 41 (19.51%)
occurrences (all)	18	10
ORAL HERPES		
subjects affected / exposed	0 / 31 (0.00%)	1 / 41 (2.44%)
occurrences (all)	0	1
RESPIRATORY TRACT INFECTION		
subjects affected / exposed	0 / 31 (0.00%)	1 / 41 (2.44%)
occurrences (all)	0	1
TOOTH ABSCESS		
subjects affected / exposed	1 / 31 (3.23%)	1 / 41 (2.44%)
occurrences (all)	1	1
TOOTH INFECTION		
subjects affected / exposed	0 / 31 (0.00%)	1 / 41 (2.44%)
occurrences (all)	0	1
VIRAL INFECTION		
subjects affected / exposed	1 / 31 (3.23%)	1 / 41 (2.44%)
occurrences (all)	1	1
FOLLICULITIS		
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)
occurrences (all)	1	0
EYE INFECTION		
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)
occurrences (all)	1	0
CORONAVIRUS INFECTION		
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)
occurrences (all)	1	0
CONJUNCTIVITIS		

subjects affected / exposed	2 / 31 (6.45%)	0 / 41 (0.00%)
occurrences (all)	2	0
BRONCHITIS		
subjects affected / exposed	2 / 31 (6.45%)	0 / 41 (0.00%)
occurrences (all)	2	0
GANGRENE		
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)
occurrences (all)	1	0
SINUSITIS		
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)
occurrences (all)	1	0
RESPIRATORY TRACT INFECTION VIRAL		
subjects affected / exposed	2 / 31 (6.45%)	0 / 41 (0.00%)
occurrences (all)	2	0
PNEUMONIA		
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)
occurrences (all)	1	0
PERIODONTITIS		
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)
occurrences (all)	1	0
ONYCHOMYCOSIS		
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)
occurrences (all)	1	0
LOCALISED INFECTION		
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)
occurrences (all)	1	0
HERPES SIMPLEX		
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)
occurrences (all)	1	0
GASTROINTESTINAL INFECTION		
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)
occurrences (all)	1	0
SKIN INFECTION		
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)
occurrences (all)	1	0

URINARY TRACT INFECTION			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences (all)	2	0	
WOUND INFECTION			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences (all)	1	0	
UPPER RESPIRATORY TRACT INFECTION			
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)	
occurrences (all)	1	0	
Metabolism and nutrition disorders			
DECREASED APPETITE			
subjects affected / exposed	0 / 31 (0.00%)	5 / 41 (12.20%)	
occurrences (all)	0	5	
HYPERCALCAEMIA			
subjects affected / exposed	1 / 31 (3.23%)	1 / 41 (2.44%)	
occurrences (all)	1	1	
HYPERCHOLESTEROLAEMIA			
subjects affected / exposed	1 / 31 (3.23%)	2 / 41 (4.88%)	
occurrences (all)	1	2	
HYPERKALAEMIA			
subjects affected / exposed	1 / 31 (3.23%)	1 / 41 (2.44%)	
occurrences (all)	1	1	
HYPERLIPASAEMIA			
subjects affected / exposed	1 / 31 (3.23%)	1 / 41 (2.44%)	
occurrences (all)	1	1	
HYPERURICAEMIA			
subjects affected / exposed	0 / 31 (0.00%)	1 / 41 (2.44%)	
occurrences (all)	0	1	
HYPOPHOSPHATAEMIA			
subjects affected / exposed	2 / 31 (6.45%)	1 / 41 (2.44%)	
occurrences (all)	4	1	
TYPE 2 DIABETES MELLITUS			
subjects affected / exposed	2 / 31 (6.45%)	0 / 41 (0.00%)	
occurrences (all)	2	0	
VITAMIN D DEFICIENCY			

subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)
occurrences (all)	1	0
DIABETES MELLITUS		
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)
occurrences (all)	1	0
FOLATE DEFICIENCY		
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)
occurrences (all)	1	0
GOUT		
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)
occurrences (all)	1	0
HYPERAMYLASAEMIA		
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)
occurrences (all)	1	0
HYPERGLYCAEMIA		
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)
occurrences (all)	1	0
HYPERNATRAEMIA		
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)
occurrences (all)	2	0
HYPERPROTEINAEMIA		
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)
occurrences (all)	1	0
HYPOALBUMINAEMIA		
subjects affected / exposed	1 / 31 (3.23%)	0 / 41 (0.00%)
occurrences (all)	1	0
HYPONATRAEMIA		
subjects affected / exposed	2 / 31 (6.45%)	0 / 41 (0.00%)
occurrences (all)	2	0
IRON DEFICIENCY		
subjects affected / exposed	2 / 31 (6.45%)	0 / 41 (0.00%)
occurrences (all)	2	0



## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
27 October 2008	Amendment 1: The rationale for this amendment was to allow patients who recently started their treatment with Imatinib to enter this trial. A transfer from other centers to the study centers was manageable without leaving the patient untreated. Often patients were treated in this stage of the disease in centers where no clinical trials can be offered. This amendment allowed these patients to be treated also in clinical trials and alleviated the recruitment
01 September 2009	Amendment 2: With this amendment the follow up period was extended. Patients were treated and followed until tumor progression. The visits were done 3 monthly.
10 June 2011	Amendment 3: This protocol amendment included the opportunity for patients to discontinue the study prematurely to receive the standard treatment imatinib for gastrointestinal stromal tumors (GIST). The decision for protocol amendment was performed in accordance to a Novartis decision taken on May 5, 2011 to discontinue the ongoing clinical trials with nilotinib in GIST.
06 January 2014	Amendment 4: Novartis took the decision to discontinue the ongoing clinical trials with nilotinib in GIST (CAMN107G2301 and CAMN107DDE05). The enrollment of this study (CAMN107DDE06) was re-opened in order to ensure continued access to nilotinib to the patients of the trials CAMN107G2301 trial and CAMN107DDE05 in Germany.
26 November 2018	<p>Amendment 5: The primary purposes of the amendment are:</p> <p>To remove the pharmacokinetic analysis from the protocol. The pharmacokinetic of nilotinib have been explored very well in human and new results are not expected from further analysis of pharmacokinetic samples.</p> <p>To reduce the burden to the patients, the visit schedule will be adapted to every 6 month. Additionally visits between the 6-month-period are at the discretion of the investigator and/or local physician and will be done as a local routine</p>

Notes:

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

Due to EudraCT system limitations, which EMA is aware of, data using 9999 as data points in this record are not an accurate representation of the clinical trial results. Please use <https://www.novctrd.com/CtrdWeb/home.nov> for complete trial results.

Notes: